Literature DB >> 7193515

Content and characterization of plasminogen activators in human lung tumors and normal lung tissue.

G Markus, H Takita, S M Camiolo, J G Corasanti, J L Evers, G H Hobika.   

Abstract

The plasminogen activator content of surgically removed lung cancers, as well as that of adjacent normal lung tissue has been determined quantitatively. Optimum conditions for the quantitative extraction have been worked out using a modification of the technique described by Nagy et al. (Int. J. Cancer, 19:614-620, 1977) which utilizes a buffered solution of the non-ionic detergent Triton X-100. Plasminogen activator was significantly elevated in the tumors (2.5- to 4.3-fold over the normal lung, depending on sample selection and other criteria), although individual variations between tumors were extremely large. No significant correlation was found between the histopathological character of the tumors and the activator content, or between invasiveness and activator content. Using rabbit antibody formed against purified urokinase as an inhibitor of activator action, it was found that lung tumors contain a urokinase-like enzyme as the predominant plasminogen activator, while the activator content of the adjacent normal lung tissue consists of some urokinase-like enzyme, but mostly of an enzyme which is not inhibited by the antibody. The urokinase-like activator has been purified approximately 20,000-fold from lung tumors by the combination of two affinity chromatographic procedures, and was compared with purified urokinase with a molecular weight of 55,000 on all criteria used, the lung tumor activator was identical to urokinase.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7193515

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  32 in total

1.  Expression of urokinase-type plasminogen activator, stromelysin 1, stromelysin 3, and matrilysin genes in lung carcinomas.

Authors:  I Bolon; M Devouassoux; C Robert; D Moro; C Brambilla; E Brambilla
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

3.  Secretion of plasminogen activator inhibitor by normal rat pleural leukocytes in culture.

Authors:  X Y Li; G M Brown; D Lamb; K Donaldson
Journal:  Lung       Date:  1990       Impact factor: 2.584

4.  Identification of a plasminogen activator derived from nasopharyngeal carcinoma.

Authors:  T Kosugi; G W Huang; M Nakamura; S Koja; H T Nong
Journal:  Eur Arch Otorhinolaryngol       Date:  1990       Impact factor: 2.503

5.  Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation.

Authors:  J M Edelberg; M Weissler; S V Pizzo
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

6.  The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.

Authors:  S M Abidi; E W Howard; J J Dmytryk; J T Pento
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

7.  Plasminogen activator activity in clonogenic cell populations separated from a murine fibrosarcoma.

Authors:  B Nagy; D J Grdina
Journal:  Clin Exp Metastasis       Date:  1989 Mar-Apr       Impact factor: 5.150

8.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

9.  Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Authors:  M Plebani; L Herszènyi; P Carraro; M De Paoli; G Roveroni; R Cardin; Z Tulassay; R Naccarato; F Farinati
Journal:  Clin Exp Metastasis       Date:  1997-07       Impact factor: 5.150

10.  Elevated urokinase-type plasminogen activator plasma levels are associated with deterioration of liver function but not with hepatocellular carcinoma.

Authors:  S Sato; T Higashi; S Ouguchi; N Hino; T Tsuji
Journal:  J Gastroenterol       Date:  1994-12       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.